We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




High-Sensitivity Troponin Demonstrates Potential for Diagnosing Acute Coronary Syndrome

By LabMedica International staff writers
Posted on 24 Sep 2024

Chest pain is a common yet difficult symptom for general practitioners to assess, as it can stem from both serious and benign conditions. More...

Now, a new study has found that high-sensitivity troponin tests have the potential to diagnose acute coronary syndrome in primary care settings.

In the study, researchers at the Leiden University Medical Center (Leiden, The Netherlands) evaluated the effectiveness of various risk assessment tools, including clinical decision rules and troponin tests, in helping general practitioners rule out acute coronary syndrome in patients presenting with chest pain. They conducted a systematic review of studies involving adult patients with chest pain in primary care. The review included studies that assessed the diagnostic accuracy of different clinical decision rules and troponin point-of-care tests, both conventional and high-sensitivity, for identifying acute coronary syndrome, including heart attacks. These tools were compared to the unaided clinical judgment of general practitioners.

The review, which included 14 studies, revealed that some clinical decision rules without troponin improved safety. However, none consistently outperformed the unaided judgment of general practitioners in ruling out acute coronary syndrome. Conventional troponin tests, when used alone, did not meet the required diagnostic accuracy, making them less reliable in primary care. High-sensitivity troponin tests demonstrated the greatest diagnostic accuracy but require further prospective validation in primary care before being recommended for widespread use. While these tests show promise, they are not yet ready to replace clinical judgment or be used independently without additional validation.

Related Links:
Leiden University Medical Center


Gold Member
Collection and Transport System
PurSafe Plus®
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Silver Member
PCR Plates
Diamond Shell PCR Plates
Sperm Quality Analyis Kit
QwikCheck Beads Precision and Linearity Kit
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.